In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct

Biomaterials

Volumn 34, Issue 12, 2013, Pages 3031-3041

  Modery Pawlowski, Christa L ^a   Tian, Lewis L ^a   Ravikumar, Madhumitha ^a   Wong, Timothy L ^a   Gupta, Anirban Sen ^a  

^a Case Western Reserve University   (United States)

Author keywords

Adhesion; Aggregation; Hemostasis; Platelet mimetic; Synthetic hemostat; Tail bleed

Indexed keywords

AGGREGATION PROPERTY; BIOLOGICAL CONTAMINATION; HEMOSTASIS; IN-VITRO; IN-VIVO; LIGAND RATIO; PLATELET ADHESION; PLATELET AGGREGATION; PLATELET-MIMETIC; RELATIVE RATIOS; SCALE-UP; SHELF LIFE; SYNTHETIC HEMOSTAT; TAIL BLEED;

ADHESION; AGGLOMERATION; BIOMIMETICS; LIGANDS; LIPOSOMES; MODULATION; OPTIMIZATION; PEPTIDES; PLATELETS; SHEAR FLOW;

BLOOD SUBSTITUTES;

BIOMIMETIC MATERIAL; COLLAGEN; FIBRINOGEN MIMETIC PEPTIDE; LIPOSOME; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; HEMOSTASIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCALE UP; SHEAR FLOW; SURFACE PROPERTY; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD PLATELETS; HEMOSTASIS; LIPOSOMES; MICE; MOLECULAR MIMICRY; NANOSTRUCTURES;

EID: 84873445273     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.045     Document Type: Article

References (54)

1. Mohanty D. Current concepts in platelet transfusion. Asian J Transfus Sci 2009, 3(1):18-21.
2. Heal J.M., Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004, 18(3):149-165.
3. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962, 266:905-909.
4. Duke W.W. The relation of blood platelets to hemorrhagic disease. JAMA 1983, 250(9):1201-1209.
5. Schiffer C.A., Anderson K.C., Bennett C.L., Bernstein S., Elting L.S., Goldsmith M., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19(5):1519-1538.
6. Rebulla P. Revisitation of the clinical indications for the transfusion of platelet concentrates. Rev Clin Exp Hematol 2001, 5(3):288-312.
7. Krug E.G., Sharma G.K., Lozano R. The global burden of injuries. Am J Public Health 2000, 90(4):523-526.
8. Kauvar D.S., Lefering R., Wade C.E. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma 2006, 60(6 Suppl.):S3-S11.
9. Liumbruno G., Bennardello F., Lattanzio A., Piccoli P., Rossetti G. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009, 7(2):132-150.
10. Lee D.H., Blajchman M.A. Platelet substitutes and novel platelet products. Expert Opin Investig Drugs 2000, 9(3):457-469.
11. Reid T.J., Rentas F.J., Ketchum L.H. Platelet substitutes in the management of thrombocytopenia. Curr Hematol Rep 2003, 2(2):165-170.
12. Moroff G., Holme S. Concepts about current conditions for the preparation and storage of platelets. Transfus Med Rev 1991, 5(1):48-59.
13. Blajchman M.A. Substitutes for success. Nat Med 1999, 5(1):17-18.
14. Heddle N.M., Klama L.N., Griffith L., Roberts R., Shukla G., Kelton J.G. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993, 33(10):794-797.
15. Bordin J.O., Heddle N.M., Blajchman M.A. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994, 84(6):1703-1721.
16. Corash L. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Transfus Med Rev 1999, 13(1):18-30.
17. Seghatchian J., De Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006, 35(3):189-196.
18. Reddy H.L., Dayan A.D., Cavagnaro J., Gad S., Li J., Goodrich R.P. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008, 22(2):133-153.
19. ®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang 2009, 97(3):234-239.
20. Blajchman M.A. Bacterial contamination and proliferation during the storage of cellular blood products. Vox Sang 1998, 74(Suppl. 2):155-159.
21. Slichter S.J. Platelet refractoriness and alloimmunization. Leukemia 1998, 12(Suppl. 1):S51-S53.
22. Blajchman M.A. Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Vox Sang 1998, 74(Suppl. 2):315-319.
23. Orlin J.B., Ellis M.H. Transfusion-associated graft-versus-host disease. Curr Opin Hematol 1997, 4(6):442-448.
24. Modery-Pawlowski C.L., Tian L.L., Pan V., McCrae K.R., Mitragotri S., Sen Gupta A. Approaches to synthetic platelet analogs. Biomaterials 2012, 34(2):526-541.
25. Nishiya T., Kainoh M., Murata M., Handa M., Ikeda Y. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. Blood 2002, 100(1):136-142.
26. Teramura Y., Okamura Y., Takeoka S., Tsuchiyama H., Narumi H., Kainoh M., et al. Hemostatic effects of polymerized albumin particles bearing rGPIa/IIa in thrombocytopenic mice. Biochem Biophys Res Commun 2003, 306(1):256-260.
27. Rybak M.E.M., Renzulli L.A. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. Artif Cells Blood Substit 1993, 21(2):101-118.
28. Davies A., Judge H., May J., Glenn J., Heptinstall S. Interactions of platelets with synthocytes, a novel platelet substitute. Platelets 2002, 13(4):197-205.
29. Levi M., Friederich P.W., Middleton S., De Groot P.G., Wu Y.P., Harris R., et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 1999, 5(1):107-111.
30. Bertram J.P., Williams C.A., Robinson R., Segal S.S., Nolan T., Lavik E.B. Synthetic platelets: nanotechnology to halt bleeding. Sci Transl Med 2009, 1(11):11ra22.
31. Okamura Y., Fujie T., Nogawa M., Maruyama H., Handa M., Ikeda Y., et al. Haemostatic effects of polymerized albumin particles carrying fibrinogen gamma-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits. Transfus Med 2008, 18(3):158-166.
32. Okamura Y., Takeoka S., Eto K., Maekawa I., Fujie T., Maruyama H., et al. Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J Thromb Haemost 2009, 7(3):470-477.
33. Okamura Y., Handa M., Suzuki H., Ikeda Y., Takeoka S. New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: cooperative effects of a mixed system of fibrinogen gamma-chain dodecapeptide- or glycoprotein Ibalpha-conjugated latex beads under flow conditions. J Artif Organs 2006, 9(4):251-258.
34. Ravikumar M., Modery C.L., Wong T.L., Sen Gupta A. Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes. Bioconjug Chem 2012, Epub Jun 5.
35. Ravikumar M., Modery C.L., Wong T.L., Sen Gupta A. Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro. Biomacromolecules 2012, 13(5):1495-1502.
36. Sen Gupta A., Huang G., Lestini B.J., Sagnella S., Kottke-Marchant K., Marchant R.E. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005, 93(1):106-114.
37. Modery C.L., Ravikumar M., Wong T.L., Dzuricky M.J., Durongkaveroj N., Sen Gupta A. Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. Biomaterials 2011, 32(35):9504-9514.
38. Berger N., Sachse A., Bender J., Schubert R., Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm 2001, 223(1-2):55-68.
39. Turecek P.L., Gritsch H., Richter G., Auer W., Pichler L., Schwarz H.P. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost 1997, 77(3):591-599.
40. Hogan K., Weiler H., Lord S. Mouse models in coagulation. Thromb Haemost 2002, 87:563-574.
41. Okamura Y., Takeoka S., Teramura Y., Maruyama H., Tsuchida E., Handa M., et al. Hemostatic effects of fibrinogen gamma-chain dodecapeptide-conjugated polymerized albumin particles in vitro and in vivo. Transfusion 2005, 45(7):1221-1228.
42. Nogami K., Shima M., Giddings J.C., Takeyama M., Tanaka I., Yoshioka A. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain. Int J Hematol 2007, 85(4):317-322.
43. Chen J., Ling M., Fu X., López J.A., Chung D.W. Simultaneous exposure of sites in von Willebrand factor for glycoprotein Ib binding and ADAMTS13 Cleavage: studies with ristocetin. Arterioscler Thromb Vasc Biol 2012, 32(11):2625-2630.
44. Schneider S.W., Nuschele S., Wixforth A., Gorzelanny C., Alexander-Katz A., Netz R.R., et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A 2007, 104(19):7899-7903.
45. Vlot A.J., Koppelman S.J., Van den Berg M.H., Bouma B.N., Sixma J.J. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995, 85(11):3150-3157.
46. Reininger A.J. VWF attributes-impact on thrombus formation. Thromb Res 2008, 122(Suppl. 4):S9-S13.
47. Wang A.Y., Mo X., Chen C.S., Yu S.M. Facile modification of collagen directed by collagen mimetic peptides. J Am Chem Soc 2005, 127(12):4130-4131.
48. Mo X., An Y., Yun C.-S., Yu S.M. Nanoparticle-assisted visualization of binding interactions between collagen mimetic peptide and collagen fibers. Angew Chem 2006, 45(14):2267-2270.
49. Farndale R.W. Collagen-induced platelet activation. Blood Cells Mol Dis 2006, 36(2):162-165.
50. Coller B.S., Springer K.T., Beer J.H., Mohandas N., Scudder L.E., Norton K.J., et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992, 89(2):546-555.
51. Kawasaki T., Kaida T., Arnout J., Vermylen J., Hoylaerts M.F. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost 1999, 81(2):306-311.
52. Okamura Y., Katsuno S., Suzuki H., Maruyama H., Handa M., Ikeda Y., et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute. J Control Release 2010, 148(3):373-379.
53. Lentz B.R. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003, 42(5):423-438.
54. Chiu G.N.C., Bally M.B., Mayer L.D. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 2003, 1613(1-2):115-121.